Stage IV Uterine Corpus Cancer AJCC v8 (DBCOND0109561)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05538897	Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers	Ipatasertib Megestrol Megestrol acetate	treatment	1 / 2	recruiting
NCT04704661	Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	Ceralasertib Trastuzumab deruxtecan	treatment	1	recruiting
NCT03968406	Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers	Talazoparib	treatment	1	recruiting
NCT04498520	Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer	Abexinostat Fulvestrant Palbociclib	treatment	1	withdrawn
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	Chloride ion Cisplatin Daunorubicin Doxorubicin Fluorouracil Irinotecan Leucovorin Mitomycin Oxaliplatin Platinum	treatment	1	recruiting
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	No drug interventions	treatment	1	recruiting
NCT05269381	Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	No drug interventions	treatment	1 / 2	recruiting
NCT05786456	e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study	No drug interventions	supportive_care	Not Available	recruiting
NCT04501913	Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT03367741	Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer	No drug interventions	treatment	2	active_not_recruiting
NCT03660826	Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone	No drug interventions	treatment	2	active_not_recruiting
NCT05092373	Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax	No drug interventions	treatment	1	recruiting
NCT05691504	Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers	No drug interventions	treatment	1	recruiting
NCT03914612	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	No drug interventions	treatment	3	active_not_recruiting
NCT03008408	A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma	No drug interventions	treatment	2	active_not_recruiting